Tioguanine in the treatment of refractory coeliac disease - A single centre experience

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 3, 2012, Pages 274-281

  Tack, G J ^a   Van Asseldonk, D P ^a   Van Wanrooij, R L J ^a   Van Bodegraven, A A ^a   Mulder, C J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; NUCLEOTIDE; PREDNISONE; TIOGUANINE; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; CELIAC DISEASE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LEUKOPENIA; LIVER HYPERPLASIA; LIVER TOXICITY; LONG TERM CARE; MALE; MUSCLE SPASM; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PRIORITY JOURNAL; REFRACTORY CELIAC DISEASE TYPE I; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CELIAC DISEASE; FEMALE; FOLLOW-UP STUDIES; GUANINE NUCLEOTIDES; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THIOGUANINE; THIONUCLEOTIDES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863307381     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05154.x     Document Type: Article

References (29)

1. Cellier C, Delabesse E, Helmer C, et al,. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203-8. (Pubitemid 30446975)
2. Daum S, Cellier C, Mulder CJ,. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413-24. (Pubitemid 40753762)
3. Verbeek WH, Goerres MS, von Blomberg BM, et al,. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease. Clin Immunol 2008; 126: 48-56. (Pubitemid 350266454)
4. Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ,. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007; 56: 1373-8. (Pubitemid 47517830)
5. Malamut G, Afchain P, Verkarre V, et al,. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009; 136: 81-90.
6. Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA,. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99-107.
7. Maurino E, Niveloni S, Chernavsky A, et al,. Azathioprine in refractory sprue: results from a prospective, open-label study. Am J Gastroenterol 2002; 97: 2595-602.
8. Goerres MS, Meijer JW, Wahab PJ, et al,. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther 2003; 18: 487-94. (Pubitemid 37152289)
9. de Jong DJ, Goullet M, Naber TH,. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2004; 16: 207-12. (Pubitemid 39049659)
10. Derijks LJ, Gilissen LP, Engels LG, et al,. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-8. (Pubitemid 38703020)
11. Jharap B, Seinen ML, de Boer NK, et al,. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-9.
12. van Asseldonk DP, Jharap B, Kuik DJ, et al,. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig Liver Dis 2011; 43: 110-5.
13. Herrlinger KR, Kreisel W, Schwab M, et al,. 6-thioguanine-efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 503-8. (Pubitemid 36384809)
14. Isaacson PG, Chott A, Ott G, Stein H,. Enteropathy-associated T-cell lymphoma. In:, Swedlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer, 2008: 289-91.
15. Al-Toma A, Goerres MS, Meijer JW, et al,. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006; 4: 1322-7. (Pubitemid 44716738)
16. Oberhuber G, Granditsch G, Vogelsang H,. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999; 11: 1185-94. (Pubitemid 30433773)
17. Dervieux T, Boulieu R,. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998; 44: 551-5. (Pubitemid 28141350)
18. Bonaz B, Boitard J, Marteau P, et al,. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 18: 401-8. (Pubitemid 37070238)
19. Weersma RK, Peters FT, Oostenbrug LE, et al,. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004; 20: 843-50. (Pubitemid 39424891)
20. van Geenen EJ, de Boer NK, Stassen P, et al,. Azathioprine or mercaptopurine induced acute pancreatitis is not a disease specific phenomenon. Aliment Pharmacol Ther 2010; 31: 1322-9.
21. Austin A, Campbell E, Lane P, Elias E,. Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody. Gut 2004; 53: 1032-34. (Pubitemid 38824164)
22. Sainsbury A, Sanders DS, Ford AC,. Meta-analysis: coeliac disease and hypertransaminasaemia. Aliment Pharmacol Ther 2011; 34: 33-40.
23. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, et al,. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34: 544-54.
24. de Boer NK, de GP, Wilhelm AJ, Mulder CJ, van Bodegraven AA,. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment Pharmacol Ther 2005; 22: 447-51. (Pubitemid 41248112)
25. Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PH,. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol 2007; 102: 2265-9. (Pubitemid 47493833)
26. Daum S, Ipczynski R, Heine B, Schulzke JD, Zeitz M, Ullrich R,. Therapy with budesonide in patients with refractory sprue. Digestion 2006; 73: 60-8. (Pubitemid 43800663)
27. Jamma S, Leffler DA, Dennis M, et al,. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30-3.
28. Wahab PJ, Crusius JB, Meijer JW, Uil JJ, Mulder CJ,. Cyclosporin in the treatment of adults with refractory coeliac disease-an open pilot study. Aliment Pharmacol Ther 2000; 14: 767-74. (Pubitemid 30352744)
29. Costantino G, della TA, Lo Presti MA, Caruso R, Mazzon E, Fries W,. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis 2008; 40: 74-7. (Pubitemid 350246383)